For the quarter ending 2025-09-30, LXRX had $28,292K increase in cash & cash equivalents over the period. -$23,833K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -12,768 | -22,043 |
| Depreciation and amortization | 151 | 352 |
| Stock-based compensation | 3,444 | 6,238 |
| Amortization/accretion of debt-related costs | 402 | 803 |
| Accretion of marketable securities purchased at a discount | 732 | 2,540 |
| Other non-cash adjustments | 18 | 1,561 |
| Decrease (increase) in accounts receivable | 151 | -1,290 |
| Decrease (increase) in inventories | -10 | -63 |
| Decrease (increase) in prepaid expenses and other current assets | 358 | -806 |
| Decrease in other long-term assets | -191 | -376 |
| Decrease (increase) in accounts payable and other liabilities | -14,004 | -10,569 |
| Net cash used in operating activities | -23,833 | -26,785 |
| Purchases of property and equipment | 0 | 0 |
| Purchases of investments | 26,725 | 90,943 |
| Maturities of investments | 78,850 | 147,008 |
| Net cash provided by (used in) investing activities | 52,125 | 56,065 |
| Proceeds from issuance of common stock for equity incentive plans | 0 | 0 |
| Proceeds from issuance of preferred stock, net of fees | 0 | 0 |
| Payments for tax withholding on share-based compensation vesting | 0 | 572 |
| Repayment of debt borrowings | 0 | 45,000 |
| Other debt financing fees | 0 | 0 |
| Net cash (used in) provided by financing activities | 0 | -45,572 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 28,292 | -16,292 |
| Cash and cash equivalents at beginning of period | 66,656 | - |
| Cash and cash equivalents at end of period | 78,656 | - |
LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)